Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 2/2014

Open Access 01-12-2014 | Meeting abstract

Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada

Authors: Jodi Cameron, Jennifer Forgie, Alicia Ring, Stephanie Santucci, Caroline Rizk, Hoang Pham, John O’Quinn, William H Yang

Published in: Allergy, Asthma & Clinical Immunology | Special Issue 2/2014

Login to get access

Excerpt

Xolair ® (omalizumab) has been approved in Canada since 2004 for the treatment of moderate to severe persistent allergic asthma in patients 12 years of age. The use of omalizumab in severe persistent allergic asthma may lead to decrease health care utilization through emergency room (ER) visits, hospitalizations, visits to health care providers, as well as, decrease the use of corticosteroids and improve the overall quality of life (QoL). …
Metadata
Title
Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
Authors
Jodi Cameron
Jennifer Forgie
Alicia Ring
Stephanie Santucci
Caroline Rizk
Hoang Pham
John O’Quinn
William H Yang
Publication date
01-12-2014
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1710-1492-10-S2-A5

Other articles of this Special Issue 2/2014

Allergy, Asthma & Clinical Immunology 2/2014 Go to the issue

Meeting abstract

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study

Meeting abstract

Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant

Meeting abstract

SCIg vs. IVIg: let’s give patients the choice!

Meeting abstract

A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy

Meeting abstract

Efficacy and safety of MK-7243: a grass allergy sublingual immunotherapy tablet evaluated in Canadian adults and children

Meeting abstract

The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada